The biotech firm reported a wider Q2 loss as cash reserves surged to $186.4M following recent funding.
Sensei Biotherapeutics reported a Q2 GAAP loss of $2.84 per share, reflecting increased research and development spending. The company’s cash position strengthened significantly, rising to $186.4M as of June 30, 2026, from $21.2M at the end of 2025.
R&D expenses climbed to $9.2M from $2.5M in the prior period, driven by costs related to the PIKTOR clinical trial and manufacturing. The company did not provide revenue figures or forward guidance in the release.
No immediate market reaction was disclosed in the announcement.